Peace Dividend

I enjoyed reading Jesse H. Ausubel's article ( The Scientist, Feb. 5, 1996, page 11) because he provided an historical analysis of the increase in the number of Ph.D.'s, and offered novel ideas to change the current situation. Unfortunately, his analysis and suggestions are based on his acceptance of the current fiscal policies of the federal government. This quiet acceptance troubles me greatly, because it will hurt future generations of researchers, and significantly decrease the quality of l

Written byRobert Kokenyesi
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

I enjoyed reading Jesse H. Ausubel's article ( The Scientist, Feb. 5, 1996, page 11) because he provided an historical analysis of the increase in the number of Ph.D.'s, and offered novel ideas to change the current situation. Unfortunately, his analysis and suggestions are based on his acceptance of the current fiscal policies of the federal government. This quiet acceptance troubles me greatly, because it will hurt future generations of researchers, and significantly decrease the quality of life for our citizens. I would like to make two points explaining why this acceptance is unacceptable, and why fighting for a change in those fiscal policies must take center stage in future discussions.

As a young researcher in the biomedical field, I believe that the taxpayers expect great improvements in the detection and cure of all diseases, and this progress depends on the advances of basic biomedical research. Therefore, it is inappropriate ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies